Expression of Cyr61 (CCN1) in human oral squamous cell carcinoma: An independent marker for poor prognosis

Head and Neck

Volumn 32, Issue 12, 2010, Pages 1665-1673

  Kok, Sang Heng ^a,b,c   Chang, Hao Hueng ^a,b   Tsai, Ju Yi ^c   Hung, Hsin Chia ^d   Lin, Chiao Ying ^a   Chiang, Chun Pin ^a,b,c   Liu, Cheing Meei ^b   Kuo, Mark Yen Ping ^a,b,c  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^d MEIHO UNIVERSITY   (Taiwan)

Author keywords

CCN proteins; Cyr61; oral squamous cell carcinoma; prognosis; tumor growth

Indexed keywords

CYSTEINE RICH PROTEIN 61;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER STAGING; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MOUSE; MOUTH CARCINOMA; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; SQUAMOUS CELL CARCINOMA; TUMOR VOLUME;

ANIMALS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CYSTEINE-RICH PROTEIN 61; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, SCID; MIDDLE AGED; MOUTH NEOPLASMS; NEOPLASM TRANSPLANTATION; PROGNOSIS; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 78649657095     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.21381     Document Type: Article

References (37)

1. Parkin DM, Bray F, Ferlay J, Pisani P,. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Scully C, Bedi R,. Ethnicity and oral cancer. Lancet Oncol 2000; 1: 37-42.
3. La Vecchia C, Tavani A, Franceschi S, Levi F, Corrao G, Negri E,. Epidemiology and prevention of oral cancer. Oral Oncol 1997; 33: 302-312.
4. Notani PN,. Epidemiology and prevention of head and neck cancer: a global view. In:, Saranath D, editor. Contemporary issues in oral cancer. New Delhi: Oxford University Press; 2000. pp 1-29.
5. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ,. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-249.
6. Cruz JJ, Ocaña A, Navarro M, Barco ED, Fonseca E,. New options in the treatment of locally advanced head and neck cancer: role for induction chemotherapy. Cancer Treat Rev 2008; 34: 268-274.
7. Subdo J, Reith A,. The evolution of predictive oncology and molecular-based therapy for oral cancer prevention. Int J Cancer 2005; 115: 339-345.
8. Lippman SM, Sudbo J, Hong WK,. Oral cancer prevention and the evolution of molecular-targeted drug development. J Clin Oncol 2005; 23: 346-356.
9. Leask A, Abraham DJ,. All in the CCN family: essential matricellular signaling modulators emerge from the bunker. J Cell Sci 2006; 119: 4803-4810.
10. Lau LF, Lam SC,. The CCN family of angiogenic regulators: the integrin connection. Exp Cell Res 1999; 248: 44-57.
11. Brigstock DR,. The CCN family: a new stimulus package. J Endocrinol 2003; 178: 169-175.
12. Perbal B,. CCN proteins: multifunctional signalling regulators. Lancet 2004; 363: 62-64.
13. Menendez JA, Mehmi I, Griggs DW, Lupu R,. The angiogenic factor CYR61 in breast cancer: molecular pathology and therapeutic perspectives. Endocr Relat Cancer 2003; 10: 141-152.
14. Babic AM, Kireeva ML, Kolesnikova TV, Lau LF,. CYR61, a product of a growth factor-inducible immediate early gene, promotes angiogenesis and tumor growth. Proc Natl Acad Sci U S A 1998; 95: 6355-6360.
15. Lin MT, Zuon CY, Chang CC, et al. Cyr61 induces gastric cancer cell motility/invasion via activation of the integrin/nuclear factor-kappaB/ cyclooxygenase-2 signaling pathway. Clin Cancer Res 2005; 11: 5809-5820.
16. Tsai MS, Hornby AE, Lakins J, Lupu R,. Expression and function of CYR61, an angiogenic factor, in breast cancer cell lines and tumor biopsies. Cancer Res 2000; 60: 5603-5607.
17. Xie D, Miller CW, O'Kelly J, et al. Breast cancer. Cyr61 is overexpressed, estrogen-inducible, and associated with more advanced disease. J Biol Chem 2001; 276: 14187-14194.
18. Sampath D, Winneker RC, Zhang Z,. Cyr61, a member of the CCN family, is required for MCF-7 cell proliferation: regulation by 17beta-estradiol and overexpression in human breast cancer. Endocrinology 2001; 142: 2540-2548.
19. Tsai MS, Bogart DF, Li P, Mehmi I, Lupu R,. Expression and regulation of Cyr61 in human breast cancer cell lines. Oncogene 2002; 21: 964-973.
20. Tsai MS, Bogart DF, Castaneda JM, Li P, Lupu R,. Cyr61 promotes breast tumorigenesis and cancer progression. Oncogene 2002; 21: 8178-8185.
21. Gery S, Xie D, Yin D, et al. Ovarian carcinomas: CCN genes are aberrantly expressed and CCN1 promotes proliferation of these cells. Clin Cancer Res 2005; 11: 7243-7254.
22. Xie D, Yin D, Wang HJ, et al. Levels of expression of CYR61 and CTGF are prognostic for tumor progression and survival of individuals with gliomas. Clin Cancer Res 2004; 10: 2072-2081.
23. Xie D, Yin D, Tong X, et al. Cyr61 is overexpressed in gliomas and involved in integrin-linked kinase-mediated Akt and beta-catenin-TCF/Lef signaling pathways. Cancer Res 2004; 64: 1987-1996.
24. Pilarsky CP, Schmidt U, Eissrich C, et al. Expression of the extracellular matrix signaling molecule Cyr61 is downregulated in prostate cancer. Prostate 1998; 36: 85-91.
25. Sampath D, Zhu Y, Winneker RC, Zhang Z,. Aberrant expression of Cyr61, a member of the CCN (CTGF/Cyr61/Cef10/NOVH) family, and dysregulation by 17 beta-estradiol and basic fibroblast growth factor in human uterine leiomyomas. J Clin Endocrinol Metab 2001; 86: 1707-1715.
26. Tong X, Xie D, O'Kelly J, Miller CW, Muller-Tidow C, Koeffler HP,. Cyr61, a member of CCN family, is a tumor suppressor in non-small cell lung cancer. J Biol Chem 2001; 276: 47709-47714.
27. Tong X, O'Kelly J, Xie D, et al. Cyr61 suppresses the growth of non-small-cell lung cancer cells via the beta-catenin-c-myc-p53 pathway. Oncogene 2004; 23: 4847-4855.
28. Chien W, Kumagai T, Miller CW, et al. Cyr61 suppresses growth of human endometrial cancer cells. J Biol Chem 2004; 279: 53087-53096.
29. Kang CJ, Chen YJ, Liao CT, et al. Transcriptome profiling and network pathway analysis of genes associated with invasive phenotype in oral cancer. Cancer Lett 2009; 284: 131-140.
30. Kuo MY, Hsu HY, Kok SH, et al. Prognostic role of p27(Kip1) expression in oral squamous cell carcinoma in Taiwan. Oral Oncol 2002; 38: 172-178.
31. Kok SH, Hong CY, Lin SK, Lee JJ, Chiang CP, Kuo MY,. Establishment and characterization of a tumorigenic cell line from areca quid and tobacco smoke-associated buccal carcinoma. Oral Oncol 2007; 43: 639-647.
32. Cha D, O'Brien P, O'Toole EA, Woodley DT, Hudson LG,. Enhanced modulation of keratinocyte motility by transforming growth factor-alpha (TGF-alpha) relative to epidermal growth factor (EGF). J Invest Dermatol 1996; 106: 590-597.
33. Hanahan D, Weinberg RA,. The hallmarks of cancer. Cell 2000; 100: 57-70.
34. Moritani NH, Kubota S, Nishida T, et al. Suppressive effect of overexpressed connective tissue growth factor on tumor cell growth in a human oral squamous cell carcinoma-derived cell line. Cancer Lett 2003; 192: 205-214.
35. Jiang WG, Watkins G, Fodstad O, Douglas-Jones A, Mokbel K, Mansel RE,. Differential expression of the CCN family members Cyr61, CTGF and Nov in human breast cancer. Endocr Relat Cancer 2004; 11: 781-791.
36. Abreu JG, Ketpura NI, Reversade B, De Robertis EM,. Connective-tissue growth factor (CTGF) modulates cell signalling by BMP and TGF-β. Nat Cell Biol 2002; 4: 599-604.
37. Inoki I, Shiomi T, Hashimoto G, et al. Connective tissue growth factor binds vascular endothelial growth factor (VEGF) and inhibits VEGF-induced angiogenesis. FASEB J 2002; 16: 219-221.